The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Selecting Among Second-Step Antidepressant Medication Monotherapies: Predictive Value of Clinical, Demographic, or First-Step Treatment Features
Abstract
CONTEXT: Little is known about selecting among second-step medications for major depressive disorder after intolerance or lack of remission with an initial selective serotonin reuptake inhibitor. OBJECTIVE: To determine whether sociodemographic, clinical, or first-step treatment features predict remission with or intolerance overall or differentially to any 1 of 3 second-step medications after an unsatisfactory outcome with citalopram hydrobromide. DESIGN: An equipoise stratified randomized study. Participants were recruited from July 17, 2001, through April 20, 2004. SETTING: Public or private sector primary care (n = 18) and psychiatric care (n = 23) settings across the United States. PARTICIPANTS: Representative outpatients aged 18 to 75 years with nonpsychotic major depressive disorder (N = 727). INTERVENTIONS: Sustained-release bupropion hydrochloride was started at 150 mg/d and incrementally increased to 400 mg/d. Sertraline hydrochloride was started at 50 mg/d and incrementally increased to 200 mg/d. Extended-release venlafaxine hydrochloride was started at 37.5 mg/d and incrementally increased to 375 mg/d. MAIN OUTCOME MEASURES: The 16-item Quick Inventory of Depressive Symptomatology, Self-Rated and the Frequency, Intensity, and Burden of Side Effects Rating. RESULTS: Remission was more likely among participants who were white, employed, cohabiting or married, or privately insured or who had prior intolerance to citalopram or at least a response to citalopram, and no prior suicide attempts. Remission was less likely among participants with concurrent generalized anxiety, obsessive-compulsive, panic, or posttraumatic stress disorders; social phobia; anxious or melancholic features; or more severe depression. Intolerance was less likely for Hispanic participants, but more likely for participants with previous suicide attempts or intolerance to citalopram. Participants with concurrent substance use were less likely to remit (odds ratio, 0.37) and more likely not to tolerate extended-release venlafaxine. Intolerance to citalopram was associated with intolerance to sertraline (P = .04). CONCLUSIONS: Clinical, demographic, and treatment history were of little value in recommending 1 medication vs another as a second-step treatment for major depressive disorder. Participants most likely to remit in the second step had less Axis I psychiatric disorder comorbidity, less social disadvantage, and at least a response to citalopram in the first step. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00021528.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 3×
“All participants received citalopram as the initial treatment (first step).(5) Participants eligible for second-step treatments had either not remitted or were intolerant to citalopram.”
MethodResultInfluentialSelf-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“Broad inclusion and minimal exclusion criteria(6) were used to enhance the generalizability of findings.(6,7) All participants received citalopram as the initial treatment (first step).”
MethodSelf-citationBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Self-citationTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Self-citationFAVA, M., ALPERT, J. E., CARMIN, C. N., WISNIEWSKI, S. R., TRIVEDI, M. H., BIGGS, M. M., SHORES-WILSON, K., MORGAN, D., SCHWARTZ, T., BALASUBRAMANI, G. K., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291704002612 · Cited by 406
Self-citationRush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S., Mundt, J. C., Shores-Wilson, K., Biggs, M. M., Woo, A., Nierenberg, A. A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.022 · Cited by 385
Self-citation
Cited by
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Cross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud, A. M., Zotti, R. J., Shehzad, Z., Gueorguieva, R., Johnson, M. K., Trivedi, M. H., Cannon, T. D., Krystal, J. H., & Corlett, P. R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00471-x · Cited by 676
Self-citationDepression and anxiety in heart failure: a review.
Celano, C. M., Villegas, A. C., Albanese, A. M., Gaggin, H. K., & Huffman, J. C. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000162 · Cited by 610
Depression and cardiac disease: epidemiology, mechanisms, and diagnosis.
Huffman, J. C., Celano, C. M., Beach, S. R., Motiwala, S. R., & Januzzi, J. L. (2013) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2013/695925 · Cited by 445
Adolescence as a unique developmental period
Jaworska, N., & MacQueen, G. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.150268 · Cited by 432
Carpenter, L. L., Janicak, P. G., Aaronson, S. T., Boyadjis, T., Brock, D. G., Cook, I. A., Dunner, D. L., Lanocha, K., Solvason, H. B., & Demitrack, M. A. (2012) · Depression and Anxiety · doi:10.1002/da.21969 · Cited by 367
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365
Depression and Cardiac Disease: A Review
Celano, C. M., & Huffman, J. C. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e31820e8106 · Cited by 320
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Trivedi, M. H., McGrath, P. J., Fava, M., Parsey, R. V., Kurian, B. T., Phillips, M. L., Oquendo, M. A., Bruder, G., Pizzagalli, D., Toups, M., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.001 · Cited by 286
Self-citationHaroon, E., Daguanno, A. W., Woolwine, B. J., Goldsmith, D. R., Baer, W. M., Wommack, E. C., Felger, J. C., & Miller, A. H. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.026 · Cited by 291
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Self-citationChekroud, A. M., Gueorguieva, R., Krumholz, H. M., Trivedi, M. H., Krystal, J. H., & McCarthy, G. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0025 · Cited by 276
Self-citationKantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00001 · Cited by 260
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205
Self-citationWilliams, L. M., Korgaonkar, M. S., Song, Y. C., Paton, R., Eagles, S., Goldstein-Piekarski, A., Grieve, S. M., Harris, A. W. F., Usherwood, T., & Etkin, A. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.89 · Cited by 195
Pizzagalli, D. A., Webb, C. A., Dillon, D. G., Tenke, C. E., Kayser, J., Goer, F., Fava, M., McGrath, P., Weissman, M., Parsey, R., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0252 · Cited by 189
Self-citationDepression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial
Arnow, B. A., Blasey, C., Williams, L. M., Palmer, D. M., Rekshan, W., Schatzberg, A. F., Etkin, A., Kulkarni, J., Luther, J. F., & Rush, A. J. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14020181 · Cited by 175
Self-citationKemp, A. H., Gordon, E., Rush, A. J., & Williams, L. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017120 · Cited by 170
Self-citationTreatment-Resistant Depression and Mortality After Acute Coronary Syndrome
Carney, R. M., & Freedland, K. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081239 · Cited by 163
Reilly, T. J., MacGillivray, S. A., Reid, I. C., & Cameron, I. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.008 · Cited by 155
Saveanu, R., Etkin, A., Duchemin, A.-M., Goldstein-Piekarski, A., Gyurak, A., Debattista, C., Schatzberg, A. F., Sood, S., Day, C. V. A., Palmer, D. M., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.018 · Cited by 151
Self-citationUher, R., Dernovsek, M. Z., Mors, O., Hauser, J., Souery, D., Zobel, A., Maier, W., Henigsberg, N., Kalember, P., Rietschel, M., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.02.014 · Cited by 112
Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10744 · Cited by 100
Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression
Vittengl, J. R., Jarrett, R. B., Weitz, E., Hollon, S. D., Twisk, J., Cristea, I., David, D., DeRubeis, R. J., Dimidjian, S., Dunlop, B. W., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040492 · Cited by 97
Self-citationMahmoudianDehkordi, S., Ahmed, A. T., Bhattacharyya, S., Han, X., Baillie, R. A., Arnold, M., Skime, M. K., John-Williams, L. S., Moseley, M. A., Thompson, J. W., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01097-6 · Cited by 95
Self-citationThe Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis
McIntyre, R. S., Lee, Y., Zhou, A. J., Rosenblat, J. D., Peters, E. M., Lam, R. W., Kennedy, S. H., Rong, C., & Jerrell, J. M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000723 · Cited by 75
Mehta, D., Raison, C. L., Woolwine, B. J., Haroon, E., Binder, E. B., Miller, A. H., & Felger, J. C. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.004 · Cited by 74
“Moreover, clinical factors associated with non-response to antidepressants including obesity, childhood maltreatment, and anxiety disorders have all been associated with increased inflammation (Danese et al., 2008, 2007; Nanni et al., 2012; Oskooilar et al., 2009; Rush et al., 2008).”
BackgroundFava, M., Targum, S. D., Nierenberg, A. A., Bleicher, L. S., Carter, T. A., Wedel, P. C., Hen, R., Gage, F. H., & Barlow, C. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.013 · Cited by 67
Self-citationA critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
Self-citationSampling bias in an internet treatment trial for depression
Donkin, L., Hickie, I. B., Christensen, H., Naismith, S. L., Neal, B., Cockayne, N. L., & Glozier, N. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.100 · Cited by 38
ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
Chang, B., Choi, Y., Jeon, M., Lee, J., Han, K.-M., Kim, A., Ham, B.-J., & Kang, J. (2019) · Genes · doi:10.3390/genes10110907 · Cited by 35
Chan, H. N., Rush, A. J., Nierenberg, A. A., Trivedi, M., Wisniewski, S. R., Balasubramani, G. K., Friedman, E. S., Gaynes, B. N., Davis, L., Morris, D., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001660 · Cited by 30
Self-citationBrignone, M., Diamand, F., Painchault, C., & Takyar, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1128404 · Cited by 30
Metadata
- Authors
- Rush, A. J., Wisniewski, S. R., Warden, D., Luther, J. F., Davis, L. L., Fava, M., Nierenberg, A. A., & Trivedi, M. H.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2008-08-04
- Volume
- 65
- Issue
- 8
- Pages
- 870
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2042944469
- Cited by
- 176
- References
- 13
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.